Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

ARA-290 (Cibinetide) vs BPC-157 — Peptide Comparison

At a Glance Quickcomparison Dose Range ARA-290 (Cibinetide) 0.16 mg–0.8 mg mg BPC-157 250–500 mcg Frequency Once daily Administration Subcutaneous injection Cycle Length Ongoing/indefinite 4-6 weeks Onset Speed Moderate (1-2 weeks) Evidence Level Moderate huma

By Recovery & Performance Peptides Editorial Team

At a Glance

Quickcomparison

Dose Range

ARA-290 (Cibinetide)

0.16 mg–0.8 mg mg

BPC-157

250–500 mcg

Frequency

Once daily

Administration

Subcutaneous injection

Cycle Length

Ongoing/indefinite

4-6 weeks

Onset Speed

Moderate (1-2 weeks)

Evidence Level

Moderate human trials (Phase 1-2)

Strong preclinical (extensive animal studies)

Efficacy

Benefitratings

Nerve Regeneration

Pain Management

Tissue Protection

Primary Benefit

Secondary Benefit

Additional Benefit

Technical Data

Compoundspecifications

Molecular Formula

C51H84N16O21

Molecular Weight

1257.31 g/mol

Half-Life

Approximately 1-2 hours in circulation, but cellular effects last much longer

Bioavailability

Subcutaneous: ~100% (complete absorption); Intravenous: Immediate

CAS Number

1208243-50-8

C62H98N16O22

1419.53 g/mol

4-6 hours

~100% (subcutaneous)

137525-51-0

Protocols

Dosingtiers

starting

1 mg

28 days

Lowest dose tested in the phase 2 sarcoidosis nerve study. A good starting point while watching how the body responds [1].

standard

4 mg

The 4 mg dose gave the strongest nerve-fiber regrowth and pain relief in the trial — better than the higher 8 mg dose [1][2].

advanced

8 mg

Highest daily dose studied in the sarcoidosis trial. It was safe but did not beat 4 mg for nerve outcomes [1].

2 mg

Three times weekly

4 weeks

An earlier sarcoidosis pilot gave 2 mg into a vein three times a week and saw improved nerve symptoms [6].

250 mcg

1-2 weeks

A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].

250-500 mcg

Twice daily

Commonly used range for tissue and tendon recovery in research practice [1][3].

500 mcg

6-8 weeks

Upper end used in practice for more demanding acute injuries [1][3].

Applications

Bestsuited for

Treating small fiber neuropathy

ARA-290 (Cibinetide) is particularly well-suited for individuals focused on treating small fiber neuropathy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Managing neuropathic pain from diabetes or sarcoidosis

ARA-290 (Cibinetide) is particularly well-suited for individuals focused on managing neuropathic pain from diabetes or sarcoidosis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Supporting nerve regeneration after injury

ARA-290 (Cibinetide) is particularly well-suited for individuals focused on supporting nerve regeneration after injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Reducing chronic inflammation

ARA-290 (Cibinetide) is particularly well-suited for individuals focused on reducing chronic inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Tendon and ligament injuries

Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair

Gut healing

IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue

Muscle injuries

Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression

Joint problems

Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties

Post-surgical recovery

Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms

Safety Profile

Sideeffects

Common

Injection Site Reactions

Headache

Dizziness

Uncommon

Elevated Blood Pressure

Fatigue

Serious

Blood Clot Formation

Injection site redness

Mild nausea

Hot/cold sensations

Allergic reaction

Research Status

Safety& evidence

FDA Status

Not FDA approved

Safety Overview

ARA-290 is a synthetic innate repair receptor agonist that has completed Phase 2 clinical trials for small fiber neuropathy and is under active development. Animal toxicology studies show a good safety margin with no organ damage or cytotoxicity at doses far exceeding therapeutic levels. Early clinical data from Phase 2 trials demonstrate tolerability with mild injection site reactions and transient headache as primary concerns. However, immunogenicity remains a potential risk with repeated dosing of synthetic peptides, requiring anti-drug antibody monitoring. Long-term safety data beyond 12 weeks does not yet exist.

Contraindications

xPolycythemia vera or erythrocytosis

xUncontrolled hypertension

xPregnancy or breastfeeding

xKnown hypersensitivity to peptides

xConcurrent use with certain cancer medications

Research compound

BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.

xPregnancy

xBreastfeeding

xActive cancer

xHistory of cancer

Decision Guide

Which isright for you?

Choose ARA-290 (Cibinetide) if...

Treating small fiber neuropathy

Managing neuropathic pain from diabetes or sarcoidosis

Supporting nerve regeneration after injury

Reducing chronic inflammation

Choose BPC-157 if...

Injury recovery

Post-surgery healing

Chronic pain management

Gut health

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

SIDE EFFECTS

Safety, Side Effects & Quality Control

Before trying BPC-157: Talk to Your Doctor: Discuss your health history, medications and gut condition. Possible Side Effects: Headache, dizziness, localized injection-site reactions. Drug Interactions: Unknown; always inform your healthcare provider about all supplements or medications you take. Product Quality: Peptide supplements can vary. Look for pharmaceutical-grade products with third-party testing for purity and sterility. Because BPC-157 isn't FDA-approved, there's no standardized manufacturing or dosing. If you and your doctor decide to try it, start low and monitor for side effects.
02

Question drills

Open a question for its connected answer.

01What If My Supplier Switched from BPC-157 to Bepecin Without Notice?+

Request a certificate of analysis showing amino-acid sequence verification and molecular weight confirmation. If the sequence matches Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and molecular weight falls within 1418–1421 Da, you've received the same compound under a different brand name. Verify purity is consistent with your previous batches (98% or higher via HPLC) and that endotoxin levels remain below 1 EU/mg. No protocol adjustment is necessary—the peptide's biological activity depends on structure, not labeling.

SOURCE / realpeptides.co ↗
02What If I Miss a Scheduled Injection During a Protocol?+

Administer the missed dose as soon as you remember if fewer than 8 hours have passed since the scheduled time, then continue the regular schedule. If more than 8 hours have passed, skip the missed dose and resume at the next scheduled administration. Do not double-dose. The peptide's 4-hour half-life means plasma levels drop significantly after 12 hours, but single missed doses during a multi-week protocol have minimal impact on overall tissue repair outcomes.

SOURCE / realpeptides.co ↗
03What If I Want to Use BPC-157 for a Chronic Tendon Injury?+

BPC-157 is not FDA-approved for human use. It remains an investigational compound legally available only for research purposes. If you're considering BPC-157 for a personal tendon issue, understand that you would be using a peptide with no established human safety profile, no standardized dosing guidelines, and no clinical oversight. Animal studies suggest doses in the range of 200–500 mcg daily for a 70 kg human (extrapolated from 10 mcg/kg rodent dosing using allometric scaling), but this is speculative. Not medical guidance. The peptide is typically administered via subcutaneous injection near the injury site, though intramuscular and oral routes have also been studied in animals.

SOURCE / realpeptides.co ↗
04What If I Start BPC-157 While Still Training Through Shin Splint Pain?+

Continue reducing training volume by 40–60% even when using BPC-157. The peptide may accelerate collagen synthesis, but mechanical stress still exceeds tissue repair capacity if you maintain full training load. A 2018 study in Sports Medicine showed that athletes who reduced mileage while using recovery protocols (including peptides) had 70% fewer recurrences at 6 months compared to those who trained through symptoms. BPC-157 doesn't override biomechanics. It supports healing only if stress is appropriately managed.

SOURCE / realpeptides.co ↗
05What If My Chronic Infection Is Viral Instead of Bacterial?+

LL-37 has documented antiviral activity against enveloped viruses including influenza A, herpes simplex virus (HSV), and human immunodeficiency virus (HIV) through membrane disruption mechanisms similar to its antibacterial action. BPC-157's immune modulation may support antiviral immunity indirectly by restoring normal interferon signalling. Published research is limited to in vitro and animal models. Human antiviral efficacy for either peptide remains unproven. The stack's theoretical applicability to viral infections exists but lacks clinical validation. Fungal infections represent a separate consideration: LL-37 shows some anti-Candida activity, but antifungal efficacy is weaker than antibacterial.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Clinical Evidence

Preclinical studies, primarily in rats, provide the bulk of evidence for the BPC 157 peptide. These demonstrate effects on tendon healing, structural recovery, and enhancement of growth hormone receptor expression in injured tissues. For example, rat models of Achilles tendon injuries showed improved functional outcomes and histological repair. Human data is sparse. Early 2000s trials from Croatia reported safety and effectiveness in small cohorts for ulcerative colitis, with phase II evidence showing no toxicity. However, no large-scale randomized controlled trials (RCTs) have been conducted on the BPC 157 peptide for musculoskeletal, wound, or CNS applications. Retrieved sources confirm insufficient high-quality human clinical trials, underscoring the reliance on animal data.

RESEARCH

BPC-157 Peptide in the Context of Broader Peptide Research

The BPC-157 peptide occupies a unique position in the landscape of synthetic research compounds. While most peptide research programs begin with a specific therapeutic target and build a synthetic molecule to match, this compound emerged from a fundamentally different direction: isolation and characterization of a naturally occurring protective sequence, followed by decades of systematic investigation into its biological activity profile. This distinction matters for researchers because it means the BPC-157 peptide’s activity range was discovered through observation rather than design. The nine tissue systems now documented in the preclinical literature were not predicted by computational models or receptor-binding assays at the outset — they were identified sequentially as researchers in different laboratories independently tested the compound against different experimental injury models and consistently found meaningful effects. That convergence of independent findings across diverse research groups adds weight to the overall body of evidence in a way that designed peptides with narrower mechanistic rationales cannot replicate. Researchers who work with the broader class of repair peptides — including TB-500, GHK-Cu, and KPV — note that the BPC-157 peptide’s documentation extends further back than most synthetic alternatives, with published mechanistic research dating to the early 1990s. This longevity of research interest is itself informative: compounds that fail to replicate across independent laboratories typically disappear from the literature within a decade. The sustained and growing body of research on this compound, spanning multiple countries, research institutions, and animal models, reflects a level of reproducibility that supports continued serious investigation. For researchers new to this space, our complete guide to research peptides provides useful foundational context for understanding where this compound fits within the broader synthetic peptide research landscape.

POTENTIAL BENEFITS

Primary Benefits

ARA-290 actively regrows small nerve fibers that die from diabetes, neuropathy, or injury. Studies show real improvements in nerve density on corneal imaging. Reduces neuropathic pain through both nerve repair and anti-inflammatory pathways. Users report decreased shooting pain and burning sensations. Protects pancreatic cells, organs, and tissues from stress damage. Works especially well in diabetes where tissues face constant oxidative harm.
05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles

bpc-157 peptide

The Complete Guide to BPC-157 Peptide: Revolutionary Research Applications and Clinical Insights for 2026 Imagine a single peptide that could revolutionize how we approach tissue repair, wound healing, and cellular rege…

Read article